Federal cannabis reform can create uneven benefits across the industry, and social-equity operators have good reason to care about who is positioned to capture them. The federal baseline changed in April 2026, though, so the old shorthand that “marijuana remains Schedule I and 280E applies to everyone” is no longer accurate.
What is the current federal position?
Federal policy now operates on two tracks. An April 2026 final rule placed FDA-approved marijuana products and marijuana regulated under qualifying state medical-marijuana licenses in Schedule III. The broader DEA proceeding over whether the remainder of marijuana should move from Schedule I to Schedule III continues.
That distinction matters for taxes because Section 280E applies to trafficking in Schedule I or II controlled substances. Public-company filings now reflect potential 280E relief for qualifying medical activity after the April change while continuing to recognize exposure for adult-use activity, earlier periods and disputed historical liabilities.
Why could reform still produce unequal outcomes?
Sasha Nutgent of Housing Works Cannabis Co. argues that federal reform should be evaluated not only by whether it improves research or tax treatment, but by which operators are positioned to capture the economic benefit. Social-equity businesses often entered legal markets with less access to inexpensive capital, real estate, purchasing power and operating infrastructure than larger incumbents.
Even where qualifying medical activity receives better federal tax treatment, equal statutory treatment does not erase unequal balance sheets. A business already carrying expensive debt or struggling for working capital enters the new environment from a very different starting point than a well-capitalized multistate operator.
What should social-equity programs measure?
License issuance is not enough. States should track whether equity operators remain open, retain meaningful ownership and decision-making authority, build equity in their businesses, refinance expensive capital and ultimately participate in the wealth created by the legal market.
That is the same measurement problem visible in Missouri’s ownership-concentration debate: counting licenses tells you who received permission to participate. It does not tell you who ultimately controls the assets or captures the value.
What should policymakers do?
First, describe the federal split accurately. Limited medical Schedule III treatment is already real, while broader rescheduling remains unresolved. Second, pair federal reform with better state-level measurement of survival, ownership retention, debt burdens and access to affordable capital. Third, make partnership and financing structures transparent enough that an equity license does not become a temporary bridge through which control quietly migrates to somebody else.
The promise of social equity was never simply to issue more licenses. It was to broaden meaningful economic participation in the legal cannabis market. Federal reform should be judged partly by whether it makes that outcome more achievable.
For the tax side of the split, see 280E Is No Longer One Cannabis Tax Story. More on the federal process lives in Cannabis Policy & Regulation.
Source: Marijuana Moment, Cannabis Could End Up Looking Like Big Pharma If Federal Rescheduling Leaves Social Equity Operators Behind (Op-Ed)
Frequently Asked Questions
- Has all marijuana moved to Schedule III? No. Qualifying state-regulated medical marijuana and FDA-approved marijuana products moved to Schedule III in April 2026, while the broader proceeding over the remainder of marijuana continues.
- Does Section 280E still matter? Yes. Adult-use activity and historical tax periods can remain exposed, while qualifying medical activity after the April change may receive different treatment.
- Why might social-equity operators still be disadvantaged? Tax relief does not erase differences in capital access, debt costs, real estate, purchasing power, infrastructure or existing market share.
- What should equity programs measure beyond licenses issued? Business survival, ownership retention, debt burdens, control, access to affordable capital and whether licensees actually build lasting economic value.